文献速递肺结节与肺癌呼吸道感染

定制决策辅助工具改善HIV感染者肺癌筛查认知

The Use of a Tailored Decision Aid to Improve Understanding of Lung Cancer Screening in People With HIV.
PubMed 文献 · Chest · 2024-07-29

本研究为单臂试点试验,纳入40例符合肺癌筛查条件的HIV感染者,使用HIV适配的个性化决策辅助工具。

要点

  • HIV感染者使用定制决策辅助工具后肺癌筛查知识显著提高。
  • 决策冲突低(中位评分0,IQR 0-5),接受度高。

核心结论

  • HIV适配的个性化决策辅助工具改善了参与者对筛查风险、获益和特征的知识,决策冲突低且接受度高。

研究设计与样本

  • 单臂试点试验,纳入40例符合肺癌筛查条件的HIV感染者。
  • 决策辅助工具包含个性化筛查建议及HIV特异性5年肺癌和全因死亡风险估计。

主要发现

  • 参与者中位年龄62岁,60%目前吸烟,中位5年肺癌风险2.0%(IQR 1.4%-3.3%),全因死亡风险4.1%(IQR 3.3%-7.9%)。
  • 个性化建议中53%为「鼓励筛查」,其余为「偏好敏感」。
  • 12题肺癌筛查知识测试相对改善60%(P<0.001),7题知识评分相对改善27%(P<0.001)。
  • 在假阳性与假阴性结果、偶发发现、肺癌特异性死亡获益及筛查可能危害等问题上显著改善。

临床怎么用

  • 该决策辅助工具可用于HIV感染者肺癌筛查的共同决策,提高知识并降低决策冲突。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with HIV are at increased risk for lung cancer and multimorbidity, complicating the balance of risks and benefits of lung cancer screening. We previously adapted Decision Precision (screenlc.com) to guide shared decision-making for lung cancer screening in people with HIV. RESEARCH QUESTION: Does an HIV-adapted and personally tailored decision aid improve shared decision-making regarding lung cancer screening in people with HIV as measured by knowledge, decisional conflict, and acceptability? STUDY DESIGN AND METHODS: This was a single-arm pilot trial of the decision aid in 40 participants with HIV eligible for lung cancer screening. The decision aid included personalized screening recommendations and HIV-specific, 5-year risk estimates of lung cancer and all-cause mortality. Participants reviewed the decision aid at shared decision-making visits and completed previsit and postvisit surveys with measures of knowledge about lung cancer screening, acceptability, and decisional conflict. RESULTS: The 40 enrolled participants were a median age of 62 years, 60% currently smoked, and they had median 5-year risks of lung cancer and all-cause mortality of 2.0% (IQR, 1.4%-3.3%) and 4.1% (IQR, 3.3%-7.9%), respectively. Personalized recommendations included "Encourage Screening" for 53% of participants and "Preference Sensitive" recommendations for the remainder. Participants showed improvement in two validated knowledge measures with relative improvement of 60% (P < 0.001) on the 12-question lung cancer screening knowledge test and 27% (P < .001) on the seven-question lung cancer screening knowledge score, with significant improvement on questions regarding false-positive and false-negative findings, incidental findings, lung cancer-specific mortality benefit, and the possible harms of screening. Participants reported low scores on the decisional conflict scale (median score, 0; interquartile range, 0-5) and high acceptability. Ninety percent of patients ultimately underwent screening within 1 month of the visit. INTERPRETATION: In our study, this HIV-adapted and personally tailored decision aid improved participants' knowledge of risks, benefits, and characteristics of screening with low decisional conflict and high acceptability. Our results indicate that this decision aid can enable high-quality shared decision-making in this high-risk population. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT04682301; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Murphy NR, Crothers K, Snidarich M, et al. The Use of a Tailored Decision Aid to Improve Understanding of Lung Cancer Screening in People With HIV. Chest. 2024. PMID: 39084517. doi:10.1016/j.chest.2024.07.147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。